InspackBook a demo
Telehealth fulfillment pharmacies

Check your telehealth partners’ claims before FDA does

Inspack reviews your telehealth clients’ websites and ads, plus your own labels, against FDA rules in minutes.

Try for free
Telehealth client page and prescription label with sourcing and equivalence claims flagged

01 / The problem

Your name is on everything your partners sell

01

Partners write the claims

You compound and dispense. They write the website. FDA can ask them who compounds and for your labels.

02

Sourcing gets blurred

White-label branding that hides the compounder is cited in FDA warning letters to telehealth brands.

03

Their ads, your exposure

Ads that mass-market compounded copies can put your 503A status and API supply at risk.

04

Volume outruns review

More telehealth clients and more pages than any pharmacist can read line by line.

One review for your partners and your labels

What we check

  • Partner websites and landing pages
  • Partner ads, emails and SMS
  • Partner branding and sourcing disclosure
  • Prescription and container labels
  • Patient information sheets
  • Outer packaging and shipping inserts

Against what

  • FDA compounded drug promotionauto-updated
  • FTC health claimsauto-updated
  • Your label templates and SOPsturned into checks
  • Your client agreementsturned into checks

Every issue comes with

  • the rule behind it
  • a suggested fix
  • a full audit trail

02 / How it works

A compliance check for every partner

01Upload

Add a partner’s materials

Upload their pages and ads with your labels and patient information for the same product.

Telehealth client: Northline Health4 files added
  • Landing pageHair regrowth, shipped to your door
    Added
  • Instagram adClinically proven, a fraction of the price
    Added
  • Prescription labelFinasteride / minoxidil topical
    Added
  • Patient information sheetPatient information
    Added
02Review

See findings across both sides

Partner claims and your labels, checked together, with the rule behind every finding.

Findings3 open
  • Client brand on label, compounder not namedFDA misbranding · sourcing
    Issue
  • Implies sameness with an FDA-approved drugFDA misbranding · equivalence
    Issue
  • Calls you an “FDA-approved pharmacy”FDA misbranding · sourcing
    Issue
03Approve

Sign off with a record

Approve before launch and re-run when content changes. Every review is kept, ready if FDA or a client asks what you checked.

03 / The difference

Telehealth partners, with and without Inspack

TodayWith Inspack
Client sites reviewed after launch, if at allReviewed before launch, re-checked on demand
New clients onboarded on trustEvery client checked the same way
Pharmacists read every pageAI flags, pharmacists decide
Proof lives in email threadsOne review record per client

Get a free partner check

Send us one telehealth client’s website and three of your labels. We return every finding with the rule behind it.

Request your checkStart free trial

04 / FAQ

Telehealth partner compliance, answered

You run the review on their materials and share the findings, each with the rule behind it. Many pharmacies make a clean review part of client onboarding.

Yes. Start with your live clients’ current pages, then review new ones as they come on.

Run the review again on the new version. Every run is kept, so you can show what was checked and when.

No. Inspack is the first pass, so your pharmacists and counsel only spend time on real findings. It doesn’t give legal advice.

No. Inspack reviews labels and promotional content. It doesn’t assess sterile or non-sterile compounding practices.

No. We review labels and marketing content, not prescriptions or patient records.

05 / Resources

Latest on Inspack

Exploring AI, compliance, and packaging validation practices

Read more
Read more